{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:45:37Z","timestamp":1791603937394,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40266-022-00948-9","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T01:02:31Z","timestamp":1655773351000},"page":"467-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Psychotropic Drug Prescription in Nursing Homes During the COVID-19 Pandemic"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-9646","authenticated-orcid":false,"given":"Alexander","family":"Ferro Uriguen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Laso Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Sannino Menicucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izaskun","family":"Iturrioz Arrechea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Alaba Trueba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Echevarr\u00eda Orella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gil Goikouria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idoia","family":"Beobide Telleria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"948_CR1","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1007\/s12603-020-1447-8","volume":"24","author":"M Inzitari","year":"2020","unstructured":"Inzitari M, Risco E, Cesari M, Buurman BM, Kuluski K, Davey V, et al. Nursing homes and long term care after COVID-19: a new era? J Nutr Health Aging. 2020;24:1042\u20136.","journal-title":"J Nutr Health Aging"},{"key":"948_CR2","unstructured":"Ministry of Social Rights and the 2030 Agenda. Report of the Working Group on COVID-19 and Residences. 2020. https:\/\/www.euskadi.eus\/gobierno-vasco\/contenidos\/documentacion\/doc_sosa_gt_covid_residencias\/es_def\/index.shtml. Accessed 20 Dec 2021."},{"key":"948_CR3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jama.2020.13484","volume":"324","author":"J Abbasi","year":"2020","unstructured":"Abbasi J. Social isolation: the other COVID-19 threat in nursing homes. JAMA. 2020;324:619\u201320.","journal-title":"JAMA"},{"key":"948_CR4","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s40520-020-01601-4","volume":"32","author":"K Palmer","year":"2020","unstructured":"Palmer K, Monaco A, Kivipelto M, Onder G, Maggi S, Michel JP, et al. The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: consequences for healthy ageing. Aging Clin Exp Res. 2020;32:1189\u201394.","journal-title":"Aging Clin Exp Res"},{"key":"948_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1001\/jamainternmed.2021.0224","volume":"181","author":"NM Stall","year":"2021","unstructured":"Stall NM, Zipursky JS, Rangrej J, Jones A, Costa AP, Hillmer MP, et al. Assessment of psychotropic drug prescribing among nursing home residents in Ontario, Canada, during the COVID-19 pandemic. JAMA Intern Med. 2021;181:861\u20133.","journal-title":"JAMA Intern Med"},{"key":"948_CR6","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S1474-4422(20)30370-7","volume":"19","author":"R Howard","year":"2020","unstructured":"Howard R, Burns A, Schneider L. Antipsychotic prescribing to people with dementia during COVID-19. Lancet Neurol. 2020;19:892.","journal-title":"Lancet Neurol"},{"key":"948_CR7","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jamda.2020.09.007","volume":"21","author":"HG Van der Roest","year":"2020","unstructured":"Van der Roest HG, Prins M, Van der Velden C, Steinmetz S, Stolte E, de Vries DH. The impact of COVID-19 measures on well-being of older long-term care facility residents in the Netherlands. J Am Med Dir Assoc. 2020;21:1569\u201370.","journal-title":"J Am Med Dir Assoc"},{"key":"948_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.regg.2008.06.001","volume":"44","author":"R L\u00f3pez Mongil","year":"2009","unstructured":"L\u00f3pez Mongil R, L\u00f3pez Trigo JA, Castrodeza Sanz FJ, Tamames G\u00f3mez S, Le\u00f3n Colombo T, Mu\u00f1oz Rivero T, et al. Prevalence of dementia in institutionalized patients. The RESYDEM study. Rev Esp Geriatr Gerontol. 2009;44:5\u201311.","journal-title":"Rev Esp Geriatr Gerontol"},{"key":"948_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1017\/S104161020700484X","volume":"19","author":"CG Lyketsos","year":"2007","unstructured":"Lyketsos CG. Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatments. Int Psychogeriatr. 2007;19:409\u201320.","journal-title":"Int Psychogeriatr"},{"key":"948_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2020.01168","volume":"11","author":"R Magierski","year":"2020","unstructured":"Magierski R, Sobow T, Schwertner E, Religa D. Pharmacotherapy of behavioral and psychological symptoms of dementia: state of the art and future progress. Front Pharmacol. 2020;11:1\u201315.","journal-title":"Front Pharmacol"},{"key":"948_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/08039480801960172","volume":"62","author":"TM Saarela","year":"2008","unstructured":"Saarela TM, Finne-Soveri H, Liedenpohja AM, Noro A. Comparing psychogeriatric units to ordinary long-term care units: are there differences in case-mix or clinical symptoms? Nord J Psychiatry. 2008;62:32\u20138.","journal-title":"Nord J Psychiatry"},{"key":"948_CR12","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"LS Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. J Am Med Assoc. 2005;294:1934\u201343.","journal-title":"J Am Med Assoc"},{"key":"948_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3233\/JAD-140579","volume":"42","author":"H Ma","year":"2014","unstructured":"Ma H, Huang Y, Cong Z, Wang Y, Jiang W, Gao S, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42:915\u201337.","journal-title":"J Alzheimers Dis"},{"key":"948_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1176\/appi.ajp.2011.11030347","volume":"169","author":"HC Kales","year":"2012","unstructured":"Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169:71\u20139.","journal-title":"Am J Psychiatry"},{"key":"948_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/ADR-170042","volume":"2","author":"SJ Ralph","year":"2018","unstructured":"Ralph SJ, Espinet AJ. Increased all-cause mortality by antipsychotic drugs: updated review and meta-analysis in dementia and general mental health care. J Alzheimers Dis Rep. 2018;2:1\u201326.","journal-title":"J Alzheimers Dis Rep."},{"key":"948_CR16","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1176\/appi.ajp.2012.12030342","volume":"169","author":"M Steinberg","year":"2012","unstructured":"Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012;169:900\u20136.","journal-title":"Am J Psychiatry"},{"key":"948_CR17","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1017\/S104161021600082X","volume":"28","author":"K Van Der Spek","year":"2016","unstructured":"Van Der Spek K, Gerritsen DL, Smalbrugge M, Nelissen-vrancken MHJMG, Wetzels RB, Smeets CHW, et al. Only 10 % of the psychotropic drug use for neuropsychiatric symptoms in patients with dementia is fully appropriate. The PROPER I-study. Int Psychogeriatr. 2016;28:1589\u201395.","journal-title":"Int Psychogeriatr"},{"key":"948_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.5694\/mja17.00857","volume":"208","author":"JL Westbury","year":"2018","unstructured":"Westbury JL, Gee P, Ling T, Brown DT, Franks KH, Bindoff I, et al. RedUSe: reducing antipsychotic and benzodiazepine prescribing in residential aged care facilities. Med J Aust. 2018;208:398\u2013403.","journal-title":"Med J Aust"},{"key":"948_CR19","first-page":"91","volume":"6","author":"J Olazar\u00e1n-Rodr\u00edguez","year":"2016","unstructured":"Olazar\u00e1n-Rodr\u00edguez J, L\u00f3pez-\u00e1lvarez J, Ag\u00fcera-ortiz LF, L\u00f3pez-arrieta JM, Beltr\u00e1n-aguirre JL, Garc\u00eda-garc\u00eda P, et al. Criterios CHROME para la acreditaci\u00f3n de centros libres de sujeciones qu\u00edmicas y para una prescripci\u00f3n de psicof\u00e1rmacos de calidad. Psicogeriatr\u00eda. 2016;6:91\u20138.","journal-title":"Psicogeriatr\u00eda."},{"key":"948_CR20","unstructured":"interRAI. Improving health care across the globe. https:\/\/interrai.org\/. Accessed 27 Apr 2022."},{"key":"948_CR21","first-page":"189","volume":"7","author":"A Lobo","year":"1979","unstructured":"Lobo A, Ezquerra J, G\u00f3mez Burgada F, Sala JM, Seva DA. El miniexamen, cognoscitivo (un \u201ctest\u201d sencillo, pr\u00e1ctico, para detectar alteraciones intelectuales en pacientes m\u00e9dicos). Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1979;7:189\u2013202.","journal-title":"Actas Luso Esp Neurol Psiquiatr Cienc Afines"},{"key":"948_CR22","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","volume":"139","author":"B Reisberg","year":"1982","unstructured":"Reisberg B, Ferris S, De Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136\u20139.","journal-title":"Am J Psychiatry"},{"key":"948_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.regg.2016.09.003","volume":"52","author":"J Ambl\u00e0s-Novellas","year":"2017","unstructured":"Ambl\u00e0s-Novellas J, Martori JC, Molist Brunet N, Oller R, G\u00f3mez-Batiste X, Espaulella PJ. Frail-VIG index: design and evaluation of a new frailty index based on the Comprehensive Geriatric Assessment. Rev Esp Geriatr Gerontol. 2017;52:119\u201327.","journal-title":"Rev Esp Geriatr Gerontol"},{"key":"948_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.4088\/JCP.v64n0607","volume":"64","author":"S Woods","year":"2003","unstructured":"Woods S. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663\u20137.","journal-title":"J Clin Psychiatry"},{"key":"948_CR25","unstructured":"Sussex Partnership NHS. Calculating equivalent doses of oral benzodiazepines Background. 2017. http:\/\/www.sussexpartnership.nhs.uk\/sites\/default\/files\/documents\/bdz_equivalent_doses_spt_guidance_update_-_0714.pdf. Accessed 27 Sep 2021."},{"key":"948_CR26","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1017\/S1041610216001150","volume":"28","author":"SIM Janus","year":"2016","unstructured":"Janus SIM, Van Manen JG, Ijzerman MJ, Zuidema SU. Psychotropic drug prescriptions in Western European nursing homes. Int Psychogeriatr. 2016;28:1775\u201390.","journal-title":"Int Psychogeriatr"},{"key":"948_CR27","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1017\/S1041610220004032","volume":"33","author":"DJ Jester","year":"2021","unstructured":"Jester DJ, Molinari V, Zgibor JC, Volicer L. Prevalence of psychotropic polypharmacy in nursing home residents with dementia: a meta-analysis. Int Psychogeriatr. 2021;33:1083\u201398.","journal-title":"Int Psychogeriatr"},{"key":"948_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/ageing\/afl131","volume":"36","author":"DD French","year":"2007","unstructured":"French DD, Campbell RR, Spehar AM, Accomando J. How well do psychotropic medications match mental health diagnoses? A national view of potential off-label prescribing in VHA nursing homes. Age Ageing. 2007;36:107\u201312.","journal-title":"Age Ageing"},{"key":"948_CR29","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s11096-016-0318-1","volume":"38","author":"JM Tordoff","year":"2016","unstructured":"Tordoff JM, Ailabouni NJ, Browne DP, Al-Sallami HS, Gray AR. Improvements in the prescribing of antipsychotics in dementia and psychogeriatric units in New Zealand. Int J Clin Pharm. 2016;38:941\u20139.","journal-title":"Int J Clin Pharm"},{"key":"948_CR30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40266-016-0414-x","volume":"33","author":"M Lapeyre-Mestre","year":"2016","unstructured":"Lapeyre-Mestre M. A review of adverse outcomes associated with psychoactive drug use in nursing home residents with dementia. Drugs Aging. 2016;33:865\u201388.","journal-title":"Drugs Aging"},{"key":"948_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e977","volume":"344","author":"KF Huybrechts","year":"2012","unstructured":"Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012;344: e977.","journal-title":"BMJ"},{"key":"948_CR32","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","volume":"72","author":"DT Maust","year":"2015","unstructured":"Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiat. 2015;72:438\u201345.","journal-title":"JAMA Psychiat"},{"key":"948_CR33","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/jgs.14111","volume":"64","author":"L Simoni-Wastila","year":"2016","unstructured":"Simoni-Wastila L, Wei YJ, Lucas JA, Brandt N, Moyo P, Huang TYJ, et al. Mortality risk of antipsychotic dose and duration in nursing home residents with chronic or acute indications. J Am Geriatr Soc. 2016;64:973\u201380.","journal-title":"J Am Geriatr Soc"},{"key":"948_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.aprim.2011.07.018","volume":"44","author":"J Velert Vila","year":"2012","unstructured":"Velert Vila J, Velert Vila MDM, Salar Ib\u00e1\u00f1ez L, Avellana Zaragoza JA, Moreno RL. Suitability of the use of benzodiazepines prescribed by the pharmacist in the elderly: a doctor-pharmacist collaboration study. Aten Primaria. 2012;44:402\u201310.","journal-title":"Aten Primaria"},{"key":"948_CR35","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"By the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2019","unstructured":"By the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67:674\u201394.","journal-title":"J Am Geriatr Soc"},{"key":"948_CR36","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1001\/jamainternmed.2018.0379","volume":"178","author":"DT Maust","year":"2018","unstructured":"Maust DT, Kim HM, Chiang C, Kales HC. Association of the centers for medicare & medicaid services\u2019 national partnership to improve dementia care with the use of antipsychotics and other psychotropics in long-term care in the United States from 2009 to 2014. JAMA Intern Med. 2018;178:640\u20137.","journal-title":"JAMA Intern Med"},{"key":"948_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/archgenpsychiatry.2010.200","volume":"68","author":"HC Kales","year":"2011","unstructured":"Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio R, et al. Trends in antipsychotic use in dementia 1999\u20132007. Arch Gen Psychiatry. 2011;68:190\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"948_CR38","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jagp.2015.07.001","volume":"23","author":"A Vasudev","year":"2015","unstructured":"Vasudev A, Shariff SZ, Liu K, Burhan AM, Herrmann N, Leonard S, et al. Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004\u20132013. Am J Geriatr Psychiatry. 2015;23:1259\u201369.","journal-title":"Am J Geriatr Psychiatry"},{"key":"948_CR39","unstructured":"FDA News. FDA expands mortality warnings on antipsychotic drugs. 2008. https:\/\/www.fdanews.com\/articles\/107752-fda-expands-mortality-warnings-on-antipsychotic-drugs. Accessed 20 Dec 2021."},{"key":"948_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.h369","volume":"350","author":"HC Kales","year":"2015","unstructured":"Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:1\u201316.","journal-title":"BMJ"},{"key":"948_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1017\/S1041610207006540","volume":"20","author":"S Konovalov","year":"2008","unstructured":"Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatrics. 2008;20:293\u2013308.","journal-title":"Int Psychogeriatrics."},{"key":"948_CR42","unstructured":"International Psychogeriatric Association. IPA complete guides to behavioral and psychological symptoms of dementia (BPSD). 2012. https:\/\/www.ipa-online.org\/publications\/guides-to-bpsd. Accessed 20 Dec 2021."},{"key":"948_CR43","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jgs.12730","volume":"62","author":"HC Kales","year":"2014","unstructured":"Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a Multidisciplinary Expert Panel for the Detroit Expert Panel on the Assessment and Management of the Neuropsychiatric Symptoms of Dementia. J Am Geriatr Soc. 2014;62:762\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"948_CR44","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/jamainternmed.2017.0746","volume":"177","author":"J Tjia","year":"2017","unstructured":"Tjia J, Hunnicutt JN, Herndon L, Blanks CR, Lapane KL, Wehry S. Association of a communication training program with use of antipsychotics in nursing homes. JAMA Intern Med. 2017;177:846\u201353.","journal-title":"JAMA Intern Med"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-022-00948-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-022-00948-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-022-00948-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T17:19:18Z","timestamp":1656177558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-022-00948-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["948"],"URL":"https:\/\/doi.org\/10.1007\/s40266-022-00948-9","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"5 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were received for the preparation of this article or the condut of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Alexander Ferro Uriguen, Esther Laso Lucas, Cinzia Sannino Menicucci, Izaskun Iturrioz Arrechea, Javier Alaba Trueba, Enrique Echevarr\u00eda Orella, Javier Gil Goikouria, and Idoia Beobide Telleria have no conflicts of interest that are directly relevant to the content of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"The study was approved (approval number: EOM2021016) for execution by the Euskadi Drug Research Ethics Committee in Vitoria-Gasteiz (Basque Country, Spain).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Given the characteristics of the study, the Euskadi Drug Research Ethics Committee exempted the need for informed consent. User identification data were anonymized in the database.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AFU formulated the research question. AFU, ELL, CSM, IIA, and IBT contributed to the conception and design of the work. AFU, IBT, EEO, and JGG analyzed the data. The first draft of the manuscript was written by AFU. AFU, ELL, CSM, IIA, JAT, EEO, JGG, and IBT critically reviewed the manuscript. All authors approved the final version for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}